Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy.

Cox, Ronald E; Parish, Marie; Oxencis, Carolyn; Mckenna, Edward; Thapa, Bicky; Chakrabarti, Sakti

Cox, Ronald E; Parish, Marie; Oxencis, Carolyn; Mckenna, Edward; Thapa, Bicky; Chakrabarti, Sakti.

Afiliação

Cox RE; Student, Medical College of Wisconsin, Wauwatosa, WI 53222, United States.
Parish M; Pharmacy, Froedtert & the Medical College of Wisconsin, Wauwatosa, WI 53222, United States.
Oxencis C; Pharmacy, Froedtert & the Medical College of Wisconsin, Wauwatosa, WI 53222, United States.
Mckenna E; Department of Hematology and Oncology, Medical College of Wisconsin, Wauwatosa, WI 53222, United States.
Thapa B; Department of Hematology and Oncology, Medical College of Wisconsin, Wauwatosa, WI 53222, United States.
Chakrabarti S; Department of Hematology and Oncology, Medical College of Wisconsin, Wauwatosa, WI 53222, United States. schakrabarti@mcw.edu.

World J Clin Oncol ; 13(7): 599-608, 2022 Jul 24.

Article em En | MEDLINE | ID: mdl-36157156

Palavras-chave

Adverse events; COVID-19; Chemotherapy; Immunotherapy; Solid tumor; Targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: World J Clin Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google